Simulations Plus, Inc (NASDAQ:SLP) Poised For Strategic Transition After Proposed Altaris Acquisition

Simulations Plus enters a near-term strategic inflection as a proposed all-cash acquisition and heightened governance scrutiny materially reshape the company’s immediate corporate backdrop and valuation context.

Recent News

Mid‑June 2026 filings and press coverage show Simulations Plus agreed to an all‑cash acquisition by affiliates of Altaris, LLC at $18.50 per share (deal subject to stockholder and regulatory approvals), while multiple law firms announced shareholder investigations into the sale process and prior guidance/impairment disclosures; earlier spring releases highlighted collaborations with NVIDIA (May 6, 2026) and with Lonza and the U.S. FDA (April 21, 2026).

Technical Analysis

ADX & Directional Indicators: ADX at 40.46 indicates a very strong underlying trend; DI+ at 31.24 with a decreasing trend signals waning upside momentum, while DI‑ at 12.35 with a decreasing trend signals retreating downside pressure — together these readings point to a strong trend that now favors consolidation around the current valuation band rather than an immediate breakout.

MACD: MACD reads 0.48 with a decreasing trend and sits below the signal line (0.59); that configuration indicates bearish momentum has re‑emerged and reduces the probability of an immediate bullish acceleration absent a MACD reversal above the signal line.

MRO (Momentum/Regression Oscillator): MRO registers at -0.12 with a peak & reversal pattern, which places the price slightly below the WMDST target and implies modest upward pressure to re‑align with valuation rather than strong downside risk.

RSI & Price Structure: RSI at 63.65 with an increasing trend signals bullish momentum without overbought extremes. Price $18.23 sits near the 12‑day EMA ($18.20, increasing) and the 20‑day average ($18.29), above the 50‑day ($16.69) and 200‑day ($16.03) averages; Bollinger bands remain narrow (upper ~ $18.36 / lower ~ $18.22), suggesting low volatility and a technical environment favoring rangebound trading until one of the directional momentum indicators confirms continuation.

Support/Resistance Context: SuperTrend lower support at $17.54 and the 12/20‑day EMA cluster provide immediate support; the proximity to the analyst price‑target mean ($17.12) and the wide target range ($9.58–$33.50) frame near‑term upside as contingent on re‑acceleration of momentum indicators.

 


Fundamental Analysis

Profitability & Margins: Operating (EBIT) margin stands at 20.56%, improving YoY by 39.77% but down QoQ by 11.30%, indicating meaningful year‑over‑year operational leverage while recent quarters show margin compression versus the prior quarter.

Earnings: Reported EPS $0.30 versus an estimate of $0.23 produced an EPS surprise of +30.44%, while forward EPS of $0.2206 implies a forward P/E of 65.61; trailing P/E registers at 54.17, reflecting elevated valuation relative to near‑term earnings power.

Revenue & Growth: Total revenue $21,886,000 with YoY revenue growth of 7.35% but a reported QoQ revenue change of -131.07% (seasonal or one‑off effects appear in the sequential figure); the YoY increase shows underlying top‑line expansion despite quarter‑to‑quarter variability.

Cash, Liquidity & Leverage: Cash $35,324,000 and cash & short‑term investments $49,990,000 support a current ratio of 5.54 and a cash ratio of 3.68; total debt $487,000 produces debt‑to‑assets of 0.32% and debt‑to‑equity of 0.35%, indicating a near‑net‑cash balance sheet and strong liquidity coverage of short‑term obligations.

Cash Flow & Capital Efficiency: Free cash flow $7,948,000 (free cash flow yield 2.42%) and operating cash flow $7,342,000 produce a cash‑to‑earnings conversion above 200% (cash flow to earnings 2.05), highlighting robust cash generation versus reported net income. Asset turnover sits at 0.146, and return on equity equals 2.57%, reflecting capital‑light software economics but modest returns on invested capital.

Valuation Notes: WMDST values the stock as EVR 12.75 while enterprise multiple stands at 47.56; high cash balances and near‑zero leverage support that valuation stance, even as elevated P/E and forward P/E reflect compressed near‑term earnings growth expectations (forward EPS $0.2206) and the market’s premium for recurring, AI‑enabled software revenue.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-05-31
REPORT DATE: 2026-07-09
NEXT REPORT DATE: 2026-10-08
CASH FLOW  Begin Period Cash Flow 25.7 M
 Operating Cash Flow 7.3 M
 Capital Expenditures -761.00 K
 Change In Working Capital 1.6 M
 Dividends Paid
 Cash Flow Delta 9.6 M
 End Period Cash Flow 35.3 M
 
INCOME STATEMENT REVENUE
 Total Revenue 21.9 M
 Forward Revenue 6.8 M
COSTS
 Cost Of Revenue 6.8 M
 Depreciation 1.4 M
 Depreciation and Amortization 1.4 M
 Research and Development 3.4 M
 Total Operating Expenses 17.4 M
PROFITABILITY
 Gross Profit 15.1 M
 EBITDA 5.9 M
 EBIT 4.5 M
 Operating Income 4.5 M
 Interest Income 344.0 K
 Interest Expense
 Net Interest Income 344.0 K
 Income Before Tax 4.8 M
 Tax Provision 1.2 M
 Tax Rate 25.614 %
 Net Income 3.6 M
 Net Income From Continuing Operations 3.6 M
EARNINGS
 EPS Estimate 0.23
 EPS Actual 0.30
 EPS Difference 0.07
 EPS Surprise 30.435 %
 Forward EPS 0.22
 
BALANCE SHEET ASSETS
 Total Assets 153.0 M
 Intangible Assets 71.4 M
 Net Tangible Assets 67.6 M
 Total Current Assets 75.1 M
 Cash and Short-Term Investments 50.0 M
 Cash 35.3 M
 Net Receivables 17.2 M
 Inventory
 Long-Term Investments 1.4 M
LIABILITIES
 Accounts Payable 2.2 M
 Short-Term Debt
 Total Current Liabilities 13.6 M
 Net Debt
 Total Debt 487.0 K
 Total Liabilities 13.9 M
EQUITY
 Total Equity 139.0 M
 Retained Earnings -25.58 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 6.88
 Shares Outstanding 20.216 M
 Revenue Per-Share 1.08
VALUATION
 Market Capitalization 328.5 M
 Enterprise Value 279.0 M
 Enterprise Multiple 47.561
Enterprise Multiple QoQ 44.688 %
Enterprise Multiple YoY -20.434 %
Enterprise Multiple IPRWA
 EV/R 12.75
CAPITAL STRUCTURE
 Asset To Equity 1.1
 Asset To Liability 10.973
 Debt To Capital 0.003
 Debt To Assets 0.003
Debt To Assets QoQ -8.357 %
Debt To Assets YoY -40.561 %
Debt To Assets IPRWA
 Debt To Equity 0.004
Debt To Equity QoQ -7.895 %
Debt To Equity YoY -39.759 %
Debt To Equity IPRWA
PRICE-BASED VALUATION
 Price To Book (P/B) 2.363
Price To Book QoQ 14.016 %
Price To Book YoY -15.297 %
Price To Book IPRWA
 Price To Earnings (P/E) 54.171
Price To Earnings QoQ 38.178 %
Price To Earnings YoY 0.456 %
Price To Earnings IPRWA
 PE/G Ratio -3.792
 Price To Sales (P/S) 15.012
Price To Sales QoQ 31.524 %
Price To Sales YoY -11.478 %
Price To Sales IPRWA
FORWARD MULTIPLES
Forward P/E 65.611
Forward PE/G -4.593
Forward P/S 48.129
EFFICIENCY OPERATIONAL
 Operating Leverage 2.029
ASSET & SALES
 Asset Turnover Ratio 0.146
Asset Turnover Ratio QoQ -14.455 %
Asset Turnover Ratio YoY 20.513 %
Asset Turnover Ratio IPRWA
 Receivables Turnover 1.237
Receivables Turnover Ratio QoQ -22.759 %
Receivables Turnover Ratio YoY -4.975 %
Receivables Turnover Ratio IPRWA
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 73.739
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 56.733
Cash Conversion Cycle Days QoQ 21.064 %
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.356
 CapEx To Revenue -0.035
 CapEx To Depreciation -0.556
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 139.0 M
 Net Invested Capital 139.0 M
 Invested Capital 139.0 M
 Net Tangible Assets 67.6 M
 Net Working Capital 61.6 M
LIQUIDITY
 Cash Ratio 3.685
 Current Ratio 5.538
Current Ratio QoQ 1.173 %
Current Ratio YoY 8.359 %
Current Ratio IPRWA
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 0.083
 Cost Of Debt 109.867 %
 Interest Coverage Ratio 6.123
Interest Coverage Ratio QoQ -20.089 %
Interest Coverage Ratio YoY 50.217 %
Interest Coverage Ratio IPRWA
 Operating Cash Flow Ratio 0.541
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 17.006
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 4.432 %
 Revenue Growth -9.901 %
Revenue Growth QoQ -131.071 %
Revenue Growth YoY 7.351 %
Revenue Growth IPRWA
 Earnings Growth -14.286 %
Earnings Growth QoQ -108.442 %
Earnings Growth YoY -131.633 %
Earnings Growth IPRWA
MARGINS
 Gross Margin 69.117 %
Gross Margin QoQ 4.003 %
Gross Margin YoY 7.999 %
Gross Margin IPRWA
 EBIT Margin 20.557 %
EBIT Margin QoQ -11.304 %
EBIT Margin YoY 39.767 %
EBIT Margin IPRWA
 Return On Sales (ROS) 20.557 %
Return On Sales QoQ -11.304 %
Return On Sales YoY 39.767 %
Return On Sales IPRWA
CASH FLOW
 Free Cash Flow (FCF) 7.9 M
 Free Cash Flow Yield 2.419 %
Free Cash Flow Yield QoQ 20.169 %
Free Cash Flow Yield YoY 18.404 %
Free Cash Flow Yield IPRWA
 Free Cash Growth 42.437 %
Free Cash Growth QoQ -37.006 %
Free Cash Growth YoY -13.183 %
Free Cash Growth IPRWA
 Free Cash To Net Income 2.223
 Cash Flow Margin 33.547 %
 Cash Flow To Earnings 2.054
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 2.388 %
Return On Assets QoQ -25.141 %
Return On Assets YoY -105.956 %
Return On Assets IPRWA
 Return On Capital Employed (ROCE) 3.227 %
 Return On Equity (ROE) 0.026
Return On Equity QoQ -24.159 %
Return On Equity YoY -104.727 %
Return On Equity IPRWA
 DuPont ROE 2.621 %
 Return On Invested Capital (ROIC) 2.407 %
Return On Invested Capital QoQ -25.779 %
Return On Invested Capital YoY 9.409 %
Return On Invested Capital IPRWA

Six-Week Outlook

Corporate developments — a proposed $18.50 per‑share acquisition and concurrent shareholder investigations — create a near‑term corporate event backdrop that will likely dominate price action over the next six weeks. Technical indicators suggest a consolidation regime around $17.50–$18.50: ADX signals a strong underlying trend while MACD momentum sits bearish below its signal line and RSI remains constructive but not extended. Fundamental liquidity and strong free cash flow provide a valuation floor; however, completion timing and approval milestones for the transaction will determine directional resolve. Expect limited volatility expansion until clear resolution of the sale process or a decisive technical signal (MACD crossing above signal) emerges.

About Simulations Plus, Inc.

Simulations Plus, Inc. (NASDAQ:SLP) develops advanced software solutions for drug discovery and development, leveraging artificial intelligence and machine learning technologies. The company operates through its Software and Services segments, offering a range of products designed to simulate and predict molecular properties and interactions. Key offerings include GastroPlus, which models the absorption and interaction of compounds in humans and animals, as well as DDDPlus and MembranePlus simulation tools. Simulations Plus also provides mechanistic and mathematical model-based products such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym. These products assist in understanding complex biological systems and drug interactions. The company offers the ADMET Predictor, a chemistry-based program that predicts molecular properties from structures, and the MedChem Designer for molecular design and analysis. Additionally, Simulations Plus delivers consulting services in clinical pharmacology, including population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, and clinical trial simulations. Their consulting services support regulatory submissions and early drug discovery efforts. The company’s clientele spans pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries, as well as academic and regulatory institutions. Established in 1996, Simulations Plus is headquartered in Lancaster, California.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.